Bayesian Adaptive D-Optimal Design with Delayed Responses

REFERENCES

• Atkinson , A. , Donev , A. , Tobias , R. ( 2007 ). Optimum Experimental Designs, with SAS . Oxford , UK : Oxford University Press .
   Google Scholar
• Berry , S. M. , Carlin , B. P. , Lee , J. , Muller , P. ( 2010 ), Bayesian Adaptive Methods for Clinical Trials . Chapman & Hall/CRC Biostatistics Series . Boca Raton , FL : Chapman & Hall/CRC .
   Google Scholar
• Buse , J. B. , Henry , R. R. , Han , J. , Kim , D. D. , Fineman , M. S. , Baron , A. D. ( 2004 ). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes . Diabetes Care 27 : 2628 – 2635 .
   PubMed Web of Science ®Google Scholar
• Bymaster , F. P. , Beedle , E. E. , Findlay , J. , Gallagher , P. T. , Krushinski , J. H. , Mitchell , S. , Robertson , D. W. , Thompson , D. C. , Wallace , L. , Wong , D. T. ( 2003 ). Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake . Bioorganic Medicinal Chemistry Letters 13 : 4477 – 4480 .
   PubMed Web of Science ®Google Scholar
• Chow , S.-C. , Chang , M. ( 2007 ). Adaptive design methods in clinical trials. Biostatistics. Boca Raton, FL: Chapman & Hall/CRC .
   Google Scholar
• Dragalin , V. ( 2006 ). Adaptive designs: Terminology and classification . Drug Information Journal 40 : 425 – 435 .
   Web of Science ®Google Scholar
• Dragalin , V. , Bornkamp , B. , Bretz , F. , Miller , F. , Padmanabhan , S. , Perevozskaya , I. , Pinheiro , J. , Smith , J. (2010). A simulation study to compare new adaptive dose-ranging designs. Statistics in Biopharmaceutical Research 2:487–512.
   Web of Science ®Google Scholar
• Dragalin , V. , Hsuan , F. , Padmanabhan , S. K. ( 2007 ). Adaptive designs for dose-finding studies based on sigmoid Emax model . Journal of Biopharmaceutical Statistics 17 : 1051 – 1070 .
   PubMed Web of Science ®Google Scholar
• Fu , H. , Manner , D. ( 2010 ). Bayesian adaptive dose-finding studies with delayed responses . Journal of Biopharmaceutical Statistics 20 : 1055 – 1070 .
   PubMed Web of Science ®Google Scholar
• Little , R. J. A. , Rubin , D. B. ( 2002 ). Statistical Analysis With Missing Data. , 2nd ed. Wiley Series in Probability and Statistics , Hoboken, NJ : Wiley .
   Google Scholar
• Mardia , K. , Marshall , R. ( 1984 ). Maximum likelihood estimation of models for residual covariance in spatial regression . Biometrika 71 : 135 – 146 .
   Web of Science ®Google Scholar
• Powell , B. ( 2005 ). FDA experience with end of Phase IIa meetings: An attempt to improve drug development decisions. www.fda.gov/OHRMS/DOCKETS/ac/05/slides/2005-4194S1_08_Powell.ppt .
   Google Scholar
• Rowland , M. , Tozer , T. N. ( 1995 ). Clinical Pharmacokinetics: Concepts and Applications. , 3rd ed. Baltimore , MD : Williams & Wilkins .
   Google Scholar
• Shao , J. ( 2003 ). Mathematical Statistics. , 2nd ed. Springer Texts in Statistics. New York , NY : Springer .
   Google Scholar
• Shargel , L. , Wu-Pong , S. , Yu , A. B. C. ( 2005 ). Applied Biopharmaceutics & Pharmacokinetics. , 5th ed. New York , NY : Appleton & Lange Reviews/McGraw-Hill, Medical Pub. Division .
   Google Scholar
• Ting , N. ( 2006 ), Dose Finding in Drug Development . Statistics for Biology and Health . New York , NY : Springer .
   Google Scholar